Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 1, 2015, Pages

  Hughes, Richard A C ^a   Mehndiratta, Man Mohan ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Janakpuri Superspecialty Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; PREDNISONE;

BODY WEIGHT GAIN; CATARACT; CLOSED ANGLE GLAUCOMA; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; GRIP STRENGTH; HIP FRACTURE; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; MOON FACE; NERVE CONDUCTION; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PEPTIC ULCER; PERCEPTIVE THRESHOLD; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; META ANALYSIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PREDNISOLONE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85011864681     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002062.pub3     Document Type: Review

References (62)

1. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory polyradiculoneuropathy more than no treatment. Annals of Neurology 1982;11(2):136-41. [PUBMED: 7041788]
2. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78(14):1079-84.
3. Van Schaik IN, Eftimov F, Van Doorn PA, Brusse E, Van den Berg LH, Van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurology 2010;9(3):245-53. [PUBMED: 20133204]
4. Lopate A, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Archives of Neurology 2005;62(2):249-54.
5. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology 2012;11(6):493-502.
6. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, et al. Frequency and time to relapse after therapy discontinuation in CIDP patients treated for six months with IVIG or IV methylprednisolone (IMC study follow-up). Journal of the Peripheral Nervous System 2013;18 Suppl:S80-1.
7. American Academy of Neurology. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41(5):617-8. [PUBMED: 2027473]
8. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment. With five-year observations of a placebo controlled case treated with corticotrophin, cortisone and prednisone. Brain 1958;81(2):157.
9. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: Clinical characteristics, course, and recommendations for diagnostic criteria. Archives of Neurology 1989;46(8):878-84.
10. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation 2010;8:14.
11. Boru UT, Erdogan H, Alp R, Tasdemir M, Yildirim S, Bilgic A, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-year follow up. Clinical Neurology & Neurosurgery 2014;118:89-93.
12. Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle and Nerve 2004;30(1):20-37.
13. Chan YC, Allen DC, Fialho D, Mills KR, Hughes RA. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(1):114-6.
14. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery and Psychiatry 2007;78(12):1349-53.
15. Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology 2010;17(2):289-94.
16. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. International Disability Studies 1991;13(2):50-4.
17. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Annals of Neurology 1981;9:134-5.
18. DeVivo DC, Engel WK. Remarkable recovery of a steroid-responsive recurrent polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry 1970;33(1):62-9.
19. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, et al. Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(7):778-83.
20. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clinic Proceedings 1975;50(11):621-37.
21. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose and myo-inositol related to sural nerve morphometry. Annals of Neurology 1980;6:590-6.
22. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 1994;36(6):838-45.
23. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, The PREDICT study group. Long term follow-up in CIDP patients treated with 6-months pulsed dexamethasone or 8-months prednisolone treatment. 2011 Meeting of the Peripheral Nerve Society June 25-29, 2011, Potomac, Maryland. Journal of the Peripheral Nervous System. 2011, issue 16 Suppl s3:S33-4.
24. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78(14):1079-84.
25. Eftimov F, Winer JB, Vermeulen M, De Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD001797.pub3]
26. Franssen H, Vermeulen M, Jennekens FG. Chronic inflammatory neuropathies. In: Emery AEH editor(s). Diagnostic Criteria for Neuromuscular Disorders. 2nd Edition. London: RSM Press, 1997:53-9.
27. Bernard PS, Keith LP. Adrenocorticotropic hormones; adrenocortical steroids and their synthetic analogues, inhibitors of the synthesis and action of adrenocortical hormones. In: Joel GH, Lee EL editor(s). Goodman and Gilman. The Pharmacological basis of Therapeutics. 9th Edition. New York: McGraw Hill, 1996:1459-84.
28. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(8):973-6.
29. Hattori N, Ichimura M, Aoki S, Nagamatsu M, Yasuda T, Kumazawa K, et al. Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. Journal of the Neurological Sciences 1998;154(1):66-71.
30. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 2001;50(2):195-201.
32. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System 2006;11(1):30-46.
33. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(1):66-70.
34. Machkhas H, Harati Y. Pulse intravenous methylprednisolone (IVMP) in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1997; Vol. 48, issue 3 Suppl:A87-8.
35. Mahdi-Rogers M, Swan AV, Van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD003280.pub4]
36. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. European Journal of Neurology 2014;21(1):28-33.
37. Mathey EK, Pollard JD. Chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences 2013;333(1-2):37-42.
38. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110(Pt 6):1617-30.
39. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, et al. INCAT Study Group. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology 2003;10(6):687-94.
40. Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD003906.pub3]
41. Merkies ISJ, Schmitz PIM, Samijn JPA, Van der Meché FGA, Toyka KV, Van Doorn PA, et al. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle and Nerve 2000;23(9):1393-401.
42. Merkies IS, Schmitz PI, Van der Meché FG, Samijn JP, Van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. Journal of Neurology, Neurosurgery and Psychiatry 2002;72(5):596-601.
43. Merkies IS, Lauria G. 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscular Disorders 2006;16(2):149-56.
44. Molenaar DSM, Van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: A pilot study. Journal of Neurology, Neurosurgery and Psychiatry 1997;62(4):388-90.
45. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Archives of Neurology 2008;65(11):1460-4.
46. Nevo Y, Pestronk A, Kornberg AJ, Connolly AM, Yee WC, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies. Neurology 1996;47(1):98-102.
47. Pedersen K, Pandolfo M, Mavroudakis N. Chronic inflammatory demyelinating polyneuropathy in a diabetic patient: deterioration after intravenous immunoglobulins treatment and favorable response to steroid treatment. Acta Neurologica Belgica 2007;107(1):14-7.
48. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. Journal of the Neurological Sciences 1976;27(4):427-58.
49. Rajabally YA, Narasimhan M, Chavada G. Electrophysiological predictors of steroid-responsiveness in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 2008;255(6):936-8.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
51. Rostasy KM, Diepold K, Buckard J, Brockmann K, Wilken B, Hanefeld F. Progressive muscle weakness after high-dose steroids in two children with CIDP. Pediatric Neurology 2003;29(3):236-8.
52. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children. II. Long term follow-up, with comparison to adults. Muscle and Nerve 1997;20(12):1569-75.
53. Sladky JT, Brown MJ, Berman PH. Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid responsive disorder. Annals of Neurology 1986;20(1):76-81.
54. Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Molecular and Cellular Endocrinology 2013;380(1-2):32-40.
55. Thomas PK, Lascelles RG, Hallpike JF, Hewer RL. Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain 1969;92(3):589-606.
56. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurology 2010;9(4):402-12.
57. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. European Journal of Neurology 2010;17(3):356-63.
58. Van Nes SI, Vanhoutte EK, Van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011;76(4):337-45.
59. Van Schaik IN, Léger J-M, Nobile-Orazio E, Cornblath DR, Hadden RDM, Koski L, et al. Multifocal motor neuropathy. In: Gilhus NE, Barnes MR, Brainin M editor(s). European Handbook of Neurological Management. 2nd Edition. Vol. 1, Oxford: Wiley-Blackwell, 2010:343-50. [MEDLINE: 13080]
60. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604-7.
61. Hughes RAC, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD002062.pub2]
62. Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD002062.]